These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26597180)

  • 1. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
    Hopkins SC; Sunkaraneni S; Skende E; Hing J; Passarell JA; Loebel A; Koblan KS
    Clin Drug Investig; 2016 Feb; 36(2):137-46. PubMed ID: 26597180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasotraline in ADHD: novel or me too drug?
    Vandana P; Arnold E
    Expert Rev Neurother; 2019 Apr; 19(4):311-315. PubMed ID: 30871381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.
    Koblan KS; Hopkins SC; Sarma K; Jin F; Goldman R; Kollins SH; Loebel A
    Neuropsychopharmacology; 2015 Nov; 40(12):2745-52. PubMed ID: 25948101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
    Kielbasa W; Quinlan T; Jin L; Xu W; Lachno DR; Dean RA; Allen AJ
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):269-76. PubMed ID: 22849510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users.
    Koblan KS; Hopkins SC; Sarma K; Gallina N; Jin F; Levy-Cooperman N; Schoedel KA; Loebel A
    Drug Alcohol Depend; 2016 Feb; 159():26-34. PubMed ID: 26794682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial.
    Adler LA; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    Int Clin Psychopharmacol; 2021 May; 36(3):117-125. PubMed ID: 33724251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
    Montoya A; Escobar R; García-Polavieja MJ; Lachno DR; Alda JÁ; Artigas J; Cardo E; García M; Gastaminza X; Gilaberte I
    J Child Neurol; 2011 Jan; 26(1):31-6. PubMed ID: 20525942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing.
    Bieck PR; Leibowitz M; Lachno DR; Ledent E; Padich R; Jhee S
    J Clin Psychopharmacol; 2016 Dec; 36(6):675-683. PubMed ID: 27755221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.
    Wigal SB; Hopkins SC; Koblan KS; Childress A; Kent JM; Tsai J; Hsu J; Loebel A; Goldman R
    J Atten Disord; 2020 Jan; 24(2):192-204. PubMed ID: 31375051
    [No Abstract]   [Full Text] [Related]  

  • 11. A Randomized, Placebo-Controlled Laboratory Classroom Study of the Efficacy and Safety of Dasotraline in Children With ADHD.
    Wigal S; Tsai J; Bates JA; Sarma K; Tortorich D; Zhu H; Goldman R
    J Atten Disord; 2022 Aug; 26(10):1357-1368. PubMed ID: 35048745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain.
    Kanodia J; Lo A; Baldwin RM; Graham RA; Bourdet DL
    Clin Pharmacokinet; 2021 Jan; 60(1):121-131. PubMed ID: 32856281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo.
    Schreiber R; Campbell U; Quinton MS; Hardy LW; Fang QK; Lew R
    Biomed Pharmacother; 2022 Sep; 153():113359. PubMed ID: 35785702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive liquid chromatography-tandem mass spectrometry method for quantitative determination of dasotraline in human plasma and its clinical application.
    Skende E; Zheng N; Chen YL
    J Pharm Biomed Anal; 2020 Nov; 191():113611. PubMed ID: 33007733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
    Ng QX
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):112-116. PubMed ID: 27813651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial.
    McElroy SL; Hudson JI; Grilo CM; Guerdjikova AI; Deng L; Koblan KS; Goldman R; Navia B; Hopkins S; Loebel A
    J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
    Kielbasa W; Pan A; Pereira A
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):377-85. PubMed ID: 25637266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium.
    Ilipilla G; Arnold LE
    Expert Opin Pharmacother; 2024 Jun; 25(8):945-956. PubMed ID: 38900676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.